Moderna MRNA

Recent headlines

• +0.10

  The WBUR Breakfast Club with Flagship Pioneering CEO and Moderna co-founder Noubar Afeyan

  wbur.org · Nov 13
• -0.66

  Assessing Merck and Moderna’s mRNA cancer vaccine

  statnews.com · Nov 13
• -0.80

  Moderna Hits Five-Year High On Sales Beat; But The Real Story Is Still Its Cancer Vaccine

  investors.com · Nov 11
• +0.84

  Moderna Earnings: Raising Fair Value Estimate as Steadying Demand for Respiratory Vaccines Supports Strong Quarter

  morningstar.com · Nov 09
• +0.51

  Moderna's Impressive Intismeran Data in Melanoma Could Form Foundation of Oncology Portfolio

  morningstar.com · Nov 08
• +0.42

  Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

  cnbc.com · Nov 06
• -0.74

  Moderna mRNA vaccine almost halves the risk of skin cancer returning

  nature.com · Oct 27
• -0.89

  Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

  arstechnica.com · Oct 26
• +0.31

  Moderna CEO eyes China partnerships despite geopolitical tensions

  asia.nikkei.com · Oct 22
• -0.72

  Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?

  nature.com · Sep 01
• -0.36

  The Moderna cancer vaccine offers hope — now we must speed up personalized therapiesPatrick A. Ott

  nature.com · Sep 01
• -0.66

  Moderna, Merck’s cancer vaccine breakthrough could open new avenue of treatment

  theglobeandmail.com · Aug 19

Latest SEC filings

• 8-K
  Current report 2026-11-13 · 8-K Item 5.02: Director or officer change
• 10-Q
  Quarterly report 2026-11-06
• 8-K
  Current report 2026-11-06
• SCHEDULE 13G/A
  Passive stake (5%+) 2026-11-05
• 8-K
  Current report 2026-09-30 · 8-K Item 5.02: Director or officer change
• 8-K
  Current report 2026-09-01 · 8-K Item 1.01: Entry into a material agreement
• SCHEDULE 13G
  Passive stake (5%+) 2026-08-12
• SCHEDULE 13G/A
  Passive stake (5%+) 2026-08-06
• 10-Q
  Quarterly report 2026-07-31
• 8-K
  Current report 2026-07-31
• SCHEDULE 13G/A
  Passive stake (5%+) 2026-07-24
• 8-K
  Current report 2026-07-08 · 8-K Item 5.02: Director or officer change

Plus 20 insider trading forms (Forms 3, 4, 5 and 144) in the last 90 days, not listed here.